• The NCIA will host the 7th Annual Cannabis Business Summit & Expo on December 15-17, 2021, in San Francisco
• This year’s event will feature BLOOM: A Brands Experience, designed to provide attendees with the ability to see, touch, and smell a variety of cannabis products on the expo floor
• In addition to Bloom, the conference will also feature two unique offsite tours, including a visit to the Dark Heart Nursery, as well as a unique cannabis-infused San Francisco city cruise

NCIA’s 7th Annual Cannabis Business Summit & Expo takes place at San Francisco’s Moscone Center from December 15-17, 2021. Hosted by the National Cannabis Industry Association (“NCIA”), the oldest and most influential trade association representing the legal cannabis business, the event will showcase over 125 speakers, more than 80 individual education sessions, and hundreds of exhibitors representing the full cannabis ecosystem. For the first time this year, #CannaBizSummit will debut BLOOM: A Brands Experience. A “show within a show,” BLOOM is an experiential showcase wherein licensed retailers, distributors, infused product manufacturers, and consumer enthusiasts, will have the opportunity to see, touch, and smell products from dozens of brands. The unique sensory experience will include flower, pre-roll, vapor, oil, edibles, and additional product categories. This, in addition to the ability to shop and compare the latest technology, products, and services, watch live demos, and evaluate product offerings side-by-side from hundreds of expo exhibitors. What’s more, the conference will also feature hundreds of engaging speakers, hand-selected for their expert knowledge, who will share secrets of the trade to help attendees future-proof their respective cannabis businesses – even in the backdrop of economic and environmental change. Throughout the show, attendees will be able to reconnect with colleagues and form new business connections during networking events, and even listen to podcasts on a live Podcast Stage. In addition to event’s core offerings, this year’s #CannaBizSummit offers a pair of experiential offsite tours, including a destination trip to Dark Heart Nursery and a cannabis-infused San Francisco city cruise. Please note that additional fees and registration are required for offsite tours. For more information about the Cannabis Business Summit & Expo, including event registration, visit https://cannabisbusinesssummit.com

• FingerMotion released results from the annual meeting held on November 22, 2021
• It announced the re-appointment of executive officers and its Board of Directors
• It also reported on the appointment of an independent accounting firm

FingerMotion (OTCQX: FNGR) held its annual meeting of stockholders on November 22, 2021. Among the issues covered included the election of specific figures into the company’s Board of Directors, coupled with the approval of the FNGR 2021 stock incentive plan and executive compensation. The company just announced that various matters were duly ratified and have since been implemented by its Board. They included:

• The election of Hsien Loong Wong, Leong Yew Poh, Michael Chan, and Ng Eng Ho into FingerMotion’s Board of Directors
• The re-appointment of Martin Shen as President and Chief Executive Officer and Yew Hon Lee as the Chief Financial Officer, Secretary, and Treasurer of the company
• The selection of Centurion ZD CPA & Co. as FingerMotion’s independent registered public accounting firm
• The sanction of the company’s 2021 Stock Incentive Plan
• The endorsement of the company’s executive compensation
• The acceptance of the frequency of stockholder votes on the company’s executive compensation to be presented to stockholders annually (https://ibn.fm/DwZF0)

These strategic appointments and approvals are geared towards pushing the company forward as it develops supplementary value-added technologies to market to its users. Additionally, they are laying down the foundation in what is expected to be a successful 2022 financial year. For more information, visit the company’s website at www.FingerMotion.com. NOTE TO INVESTORS: The latest news and updates relating to FNGR are available in the company’s newsroom at https://ibn.fm/FNGR

• Flora Growth recently entered into a licensing agreement to produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia, with an initial focus on the U.S. market
• The company will produce the product line using molecular tagging and authentication technology that will guarantee product verification and allay concerns of counterfeit products
• Through the licensing agreement, Flora has entered into the cannabis beverages market amid increasing demand for CBD-based products
• The recent agreement follows a November 15 announcement that FLGC had completed the acquisition of Vessel Brand Inc., an industry leader in luxury cannabis consumer technology

Internationally focused cannabis brand builder Flora Growth (NASDAQ: FLGC) recently signed a licensing agreement with Tonino Lamborghini, a luxury brand operating in the high-end designer products, hotel, beverage, and real estate segments. Under the terms of the partnership announced November 29, Flora Growth will produce and distribute Tonino Lamborghini-branded cannabis beverages across North America and Colombia (https://ibn.fm/rDa9T). The Tonino Lamborghini product line, which will be produced in Florida for initial sale in US states where cannabidiol (“CBD”) ingestible are legal, will contain CBD and other premium cannabinoids, including cannabigerol (“CBG”). In addition, Flora will produce the product line using Applied DNA Sciences, Inc.’s (NASDAQ: APDN) molecular tagging and authentication technology, ensuring product verification and substantially reducing concerns of any counterfeit products or illicit market across North America or Colombia. Notably, this practice dovetails with the new age of cannabis consumer packaged goods (“CPG”). Under the licensing deal, Flora will retain the right of first refusal to produce and distribute any CBD or CBG products around the world under the Tonino Lamborghini brand. Tonino Lamborghini, the eponymous company’s founder, launched a line of designer beverage products in the mid-90s, becoming the first entrepreneur to achieve this feat. Since then, the company has been driven by the mission to propagate the brand’s intrinsic energy through a selection of drinks. Presently, Tonino Lamborghini produces an exclusive line of signature drinks, including energy drinks, espresso coffee in three different blends, soluble chocolates in eight flavors, vodka, and wines (https://ibn.fm/CtrXa). With CBD- or tetrahydrocannabinol (“THC”)-infused alcoholic drinks currently illegal in the United States, Flora Growth plans to concentrate on Tonino Lamborghini’s non-alcoholic beverages. The company says that infusing coffee, one of the most popular beverage segments globally, with cannabinoids, for example, will serve as a strong differentiator for the product line, beyond its connection to the luxury brand, particularly with the growing demand for CBD-based products. According to an analysis by BDS Analytics, CBD now represents a booming market in the United States, where, buoyed by the emergence of marijuana dispensaries, CBD sales are projected to reach $20 billion by 2024, up from $1.9 billion in 2018. This figure will translate to a global market share of 44%, considering BDS forecasts that the global CBD market will reach $45 billion in 2024 (https://ibn.fm/Z5cQT). Further, BDS notes that as the popularity of CBD has gathered momentum, piquing the interest of even more consumers, so too has it persuaded the established corporations to create CBD products. Flora Growth’s recent partnership with Tonino Lamborghini is a testament to this statement. “We are excited to partner with such a well-known luxury brand as Tonino Lamborghini, which already boasts a very successful line of beverages and aligns with Flora’s brand portfolio of high-end products,” stated Flora Growth CEO Luis Merchan. “This partnership is yet another step in the execution of Flora’s strategic plan to build a world-class house of brands and is also a major component of our sales and distribution strategy in the lucrative US market.” The company’s recent licensing agreement follows on the heels of the acquisition of Vessel Brand Inc. (“Vessel”), a Carlsbad, California-headquartered industry leader in luxury cannabis consumer technology. Boasting a proven go-to-market strategy for direct-to-consumer sales for the US and global cannabis markets that has resulted in rapid growth since inception in 2018, Vessel will serve as a critical component of FLGC’s North American cannabis strategy (https://ibn.fm/MSIxx). Flora Growth, which operates one of the largest outdoor cultivation facilities in the world, leverages natural, cost-effective cultivation practices to supply cannabis derivatives to its diverse business divisions, including cosmetics, hemp textiles, and food and beverage. Previously, through its Kasa Wholefoods division, the company only produced non-cannabis drinks from responsibly sourced exotic Amazonian fruits. The recent partnership, therefore, marks Flora Growth’s entry into the cannabis beverages market. For more information, visit the company’s website at www.FloraGrowth.ca. NOTE TO INVESTORS: The latest news and updates relating to FLGC are available in the company’s newsroom at https://ibn.fm/FLGC

• PlantX seeks to redefine the plant-based community through e-commerce, content sharing, and community-building efforts
• With over 5,000 plant-based products, the company also promises to be the one-stop-shop for everything plant-based
• It is leveraging the internet and technology to bring its products and services closer to customers
• By doing so, it is laying down the standard operating procedures for achieving success as a plant-based e-commerce enterprise

As of 2019, the plant-based food and beverage market in North America was valued at $14.08 billion (https://ibn.fm/XehMr). Globally, it is projected that by 2027, this industry will be valued at $74.2 billion, representing a CAGR of 11.9% over the forecast period (2020-2027) (https://ibn.fm/owfWJ). This growth will be attributed to the increasing incidence of intolerance for animal proteins, a growing vegan population, the nutritional benefits offered by plant-based food, along with venture investments in plant-based food. This opportunity has seen many entrants into this space, each trying to carve out a niche and a market share for themselves. Globally, over 800 different brands and companies either focus on plant-based foods in place of animal products or have a business unit dedicated to such products (https://ibn.fm/9qd8s). In the North American market, one enterprise that is at the forefront of them all is PlantX Life (CSE: VEGA) (Frankfurt: WNT1) (OTCQB: PLTXF) PlantX’s main aim is to redefine the plant-based community. It plans to achieve this through various avenues, including e-commerce, content sharing, and community-building efforts. This company is not all about making sales. Instead, it is about growing the plant-based community, educating the masses, and creating an environment where each member can thrive, grow and learn something new. PlantX promises to be the one-stop shop for everything plant-based. The company is banking on technology and the internet to bring its products and services even closer to the customers. So far, for the North American market, PlantX has over 5,000 plant-based products, with the list constantly growing as it acquires new brands and continues to develop new products. The company’s strategic locations also facilitate same-day delivery on plant-based products, ultimately improving the overall customer experience, and facilitating a comfortable plant-based lifestyle. PlantX’s recent addition of a subscription service that caters to recurring services is also a testament to its commitment to further strengthening its e-commerce model while also helping to overcome potential barriers to a healthy lifestyle such as time and cost (https://ibn.fm/yoVCD). PlantX is laying down the standard operating procedures to succeed as a plant-based e-commerce enterprise by executing its plans and achieving its objectives. Its first-mover advantage has earned it a rightful position as the leader in this space. So far, PlantX has made significant achievements as it continues to innovate, improve its products and services and find new ways to improve the plant-based community. Overall, this is helping to push the brand even further while also advancing the plant-based industry as a whole. For more information, visit the company’s websites at www.PlantX.com, www.PlantX.ca, and https://investor.plantx.com/ and view PlantX for Plant-Based Investors. NOTE TO INVESTORS: The latest news and updates relating to PLTXF are available in the company’s newsroom at https://ibn.fm/PLTXF

• Groundwork exploration kicked off in August, led by Orix Geosciences
• The survey revealed multiple areas of high merit and potential mineralization
• This complements a sediment sampling conducted back in 2001 by the Ontario Geological Survey
• With these results, StraightUp can now execute its right to acquire 100% interest in the property

In early 2021, StraightUp Resources (CSE: ST) (OTCQB: STUPF) acquired an option to purchase the Ferdinand Gold Property in Ontario and set out to explore the property for potential mineralization (https://ibn.fm/o1XoL). Groundwork exploration kicked off in the month of August, spearheaded by Orix Geosciences. On November 29, 2021, the company announced having completed all of 2021 ground exploration on the property. The study, which involved heliborne magnetic surveys, revealed multiple areas of high merit and potential mineralization, a significant achievement for the company (https://ibn.fm/Wh23o). “We now have confirmation of D2 folding and ultramafic rocks, together considered to be a primary control for high-grade gold mineralization in this region, especially the Great Bear Resources Dixie Lake Gold Project,” noted Mark Brezer, the President and Chief Executive Officer (“CEO”) of StraightUp. “This study represents a transformation of the Ferdinand Gold Project and we couldn’t be more excited about the road ahead in this unexplored and unappreciated section of the infamous Uchi subprovince,” he added. This just-concluded survey complements a sediment sampling conducted by the Ontario Geological Survey back in 2001. This study revealed distinct clustering of lake sediment samples anomalous in specific minerals that further allowed for new targets for potential mineralization to be identified. With these results, StraightUp now can execute its right to acquire 100% interest in the property, which comprises 17 mining claims comprising 354 cells spread across 7,143 hectares. The property is located within the south Uchi greenstone belt, 13 km northwest of Slate Falls town and 120 km east of Red Lake, Ontario. The conclusion of this exploration marks a significant milestone for StraightUp, particularly as it aligns with its commitment to mineral exploration and the acquisition of mineral property assets in North America. The company is determined to continue maximizing shareholder wealth as it makes discoveries at projects with great potential within the region. StraightUp also announced the closure of the 4th tranche of financing for a sum of $100,000. The money will be raised by issuing 150,000 warrants and 500,000 common shares, exercisable at $0.30 until November 15, 2023. The proceeds from the offering will fund exploration projects and property expenditures, as well as working capital. All securities issued will be subject to a 4-month hold period expiring March 16, 2022. For more information, visit the company’s website at www.StraightUpResources.com. NOTE TO INVESTORS: The latest news and updates relating to STUPF are available in the company’s newsroom at https://ibn.fm/STUPF

• Avricore Health is a point of care pharmacy services developer that is providing lab-quality testing for select health conditions at pharmacies in Canada
• Avricore’s trademarked HealthTab(TM) platform networks patients, pharmaceutical professionals and other medical providers with a patient-privacy respecting solution that helps patients monitor their conditions at local community stores without the necessity of busy doctors’ offices scheduling
• In addition to the kidney-function monitoring solution announced just recently, HealthTab is currently outfitted to provide lab results for evaluating diabetes, heart disease, COVID, RSV, and other viral exposures
• Avricore’s pilot HealthTab rollout includes sites in eastern Canada’s Ontario province and western Canada’s British Columbia, where it is gathering information that will help its plans for a broader HealthTab rollout in Canada and other nations
• Avricore anticipates strong growth of the HealthTab network in Canada, and abroad, in 2023

Point of care health testing technology innovator Avricore Health (TSX.V: AVCR) (OTCQB: AVCRF) has rolled out its trademarked HealthTab platform in select Ontario and British Columbia Shoppers Drug Mart network pharmacies and continues to add lab-accurate test functionality to its kiosks, most recently announcing a solution for monitoring kidney function. Avricore signed a non-exclusive distribution agreement in Canada with multinational medical devices and health care company Abbott Laboratories to distribute Abbott’s handheld blood chemistry analyzer, i-STAT Alinity, through Avricore’s Canadian outlets, announcing Nov. 23 that the device will help patients monitor their creatinine levels. “Understanding renal function in patients at risk from or already living with chronic disease is critical,” Avricore Health CEO Hector Bremner stated (https://ibn.fm/xhjGU). “With i-STAT Alinity and its associated test for creatinine, healthcare professionals can obtain results in approximately two minutes to detect elevated levels of creatinine that are associated with abnormal renal function.” HealthTab is a communications network solution that allows pharmacies to provide patients testing services at neighborhood stores under the direction of trained professionals, thereby granting patients localized options for monitoring their health conditions without the necessity of visits to busy doctor clinics to get lab work done. HealthTab draws real-time data from blood samples and other fluids and communicates it to patients and medical care providers, respecting patient privacy concerns as well as medical provider concerns about the accuracy of the lab tests. Avricore has established an agreement with Abbott to provide the POC testing at Avricore’s partner pharmacies using Abbott’s trademarked ID Now kiosks. Agreements in the pilot stage allow for testing for markers related to conditions such as diabetes, heart disease (https://ibn.fm/5hEOz) and viruses such as COVID’s SARS-CoV-2, RSV, influenza A and B, and strep (https://ibn.fm/Xdj0d) empowering patients who want to take a greater role in managing their conditions. Avricore’s purpose is to likewise empower community pharmacies, particularly those in Canada whose revenues were impacted by the Pan-Canadian Select Molecule Price Initiative for Generic Drugs in 2018 that reduced retail margins in reimbursements. Avricore will build on its pilot program operations, using feedback from pharmacists and patients to support a broader launch into several pharmacy chains throughout Canada, the United States and Europe. The company anticipates establishing its POC health testing kiosks in 600 locations by the end of 2023 (https://ibn.fm/5zVGD). “We’ve demonstrated a unique resilience by remaining focused on our goal of creating the world’s largest rapid testing network in pharmacy,” Bremner stated earlier this year (https://ibn.fm/ivPKX). “We are well on our way to making actionable health information more accessible for everyone and dramatically expanding our network in the coming months.” For more information, visit the company’s website at www.AvricoreHealth.com. NOTE TO INVESTORS: The latest news and updates relating to AVCRF are available in the company’s newsroom at https://ibn.fm/AVCRF

• NMRD releases fiscal Q2-2021 results, provides business update
• Highlights include pending revenue recognition, global commercial contract with MySugarWatch DuoPack Limited, appointment of Dr. Osama Hamdy to advisory board
• Company operates at intersection of $59 billion Type 2 diabetes market, $50+ billion pre-diabetic market, $60 billion wearable weight loss and wellness applications sector

Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, recently released its fiscal Q2-2021 results and provided a business update (https://ibn.fm/TX286). Financial highlights from the announcement included $26.8M cash on hand, and receipt of an initial $513,000 as deposit payment from its UK licensee as partial payment for an order of 200,000 sensors and associated devices. Management expects to convert this and future invoiced payments to revenue once the Company begins delivering the final product to its licensee, scheduled to start during Q4-2021. NMRD is currently commercializing its sugarBEAT(R) and proBEAT(TM) non-invasive and flexible continuous glucose monitors that provide actionable insights from real-time glucose monitoring to help diabetic and pre-diabetic people better manage, reverse, and prevent the onset of diabetes. The Company recently welcomed Dr. Osama Hamdy, M.D., Ph.D., to its advisory board, who will take part and advise on diabetes and metabolic health studies using Nemaura’s glucose monitoring technology. Dr. Hamdy is a senior endocrinologist and medical director, Obesity Clinic Program at the Joslin Diabetes Center and an associate professor of medicine at Harvard Medical School. Dr. Hamdy is a world-renowned thought leader in the field of obesity management in diabetes, medical nutrition and digital health. NMRD also announced the signing of a global commercial contract with MySugarWatch DuoPack Limited to provide continuous glucose monitors and sensors as Duo-Packs, to be sold with prescription-only medicines typically prescribed to people with Type 2 diabetes. “We continue to make progress in our commercializing efforts for sugarBEAT(R) in the UK and recognizing revenue from our licensee. We are also working closely with advisors to expand our footprint throughout the world to address the worldwide health crisis of diabetes using our skin-mounted needle-free CGM as an innovative solution for patients and consumers,” said Dr. Faz Chowdhury, CEO of Nemaura Medical. “Combined with our digital lifestyle management programs, we believe that our technology offering has the potential to be a key tool for the prevention and management of Type 2 diabetes. As we progress with our corporate, clinical, and regulatory milestones, we will provide future investor updates.” Founded in 2011, Nemaura initially developed a single platform technology to measure blood markers at the skin’s surface. The Company has since evolved with the creation of wearable technologies and digital health care solutions at the intersection of three rapidly growing markets: the global Type 2 diabetes market expected to reach $59 billion by 2025, the $50+ billion pre-diabetic market, and the wearable weight loss and wellness applications sector, estimated to reach $60 billion by 2023 (https://ibn.fm/0MG5U). With obesity and diabetes as the two major drivers fueling the chronic disease epidemic, NMRD is committed to preventing, managing, and reversing these conditions by offering non-invasive, affordable, and flexible glucose monitoring solutions. For more information, visit the company websites at www.NemauraMedical.com. NOTE TO INVESTORS: The latest news and updates relating to NMRD are available in the company’s newsroom at https://ibn.fm/NMRD

• Report notes significant and swift advancements in company R&D pipeline and overall business
• Preliminary data indicates CYB003 may provide significant treatment benefits that address limitations of oral psilocybin
• CYBN programs and new psychedelic chemical entities have potential to transform treatment landscape for various psychiatric and neurological conditions

Q2 2021 has been a transformative quarter for Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing psychedelics to therapeutics(TM). The company released its financial and operational report for the period recently, with notable company milestones and achievements highlighted (https://ibn.fm/ucAed). “The first half of the year has been a transformative period for Cybin that included significant and swift advancements in our research and development pipeline and overall business,” said Cybin CEO Doug Drysdale. “Through CYB003, we believe that we have identified a potentially safer treatment option for patients with depression and addiction disorders that we expect to have strong intellectual property protection and a positive pharmacokinetic profile for patients, providers and payers. We plan to move through the ongoing, remaining preclinical studies quickly and submit an investigational new drug application and clinical trial application in the second quarter of 2022¹, in the U.S. and the U.K. respectively.” Cybin’s novel deuterated psilocybin analog, CYB003, was the focus of a preclinical study designed to explore and study the substance for potential treatment of major depressive disorder and alcohol use disorder. The company recently reported preliminary data indicating that CYB003 may provide significant treatment benefits that successfully address the challenges and limitations of oral psilocybin; those benefits include improved safety through less patient variability, reduced clinic times through faster onset of action and shorter duration of effect, and lower dosing through improved brain penetration. The company noted that the study also shows the treatment may produce fewer side effects. All of this points to an overall improved patient experience. In its report, Cybin noted that it plans to complete the ongoing CYB003 preclinical studies in the first quarter of 2022. By Q2 2022, the company anticipates submitting an investigational new drug application to the U.S. Food and Drug Administration and a clinical trial application with the U.K. Medicines and Healthcare Products Regulatory Agency. Other notable company achievements during the quarter include the U.S. Drug Enforcement Agency’s approval of a Schedule I manufacturing license for Cybin’s research lab, which is located in Boston. This license will enable CYBN to expand its internal research and development capabilities. The company also received FDA approval for its IND application to proceed with a feasibility study using Kernel Flow quantitative neuroimaging technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. In addition, Cybin launched a first-of-its-kind psychedelic facilitator training program, based on EMBARK, a groundbreaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine (https://ibn.fm/zWTkO). “We continue to evolve our value-driving, patient-centered approach to potential treatments for mental health and addiction through our commitment to advancing programs such as EMBARK, that aims to facilitate psilocybin-assisted psychotherapy for frontline workers impacted by the COVID-19 pandemic, as well as targeted research using the Kernel Flow neuroimaging technology that we expect will allow us to quantitively understand the psychedelic experience in the brain as it is happening. We believe these programs combined with our proprietary psychedelic new chemical entities have the potential to transform the treatment landscape for various psychiatric and neurological conditions.” Cybin is focused on progressing psychedelic therapeutics, making it an ideal advocate and sponsor of the EMBARK approach. A leading biotechnology company, Cybin is working to progress psychedelic therapeutics by utilizing proprietary drug-discovery platforms, innovative drug-delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders. For more information, visit the company’s website at www.Cybin.com. NOTE TO INVESTORS: The latest news and updates relating to CYBN are available in the company’s newsroom at https://ibn.fm/CYBN

• The global cannabis market was valued at $22.10 billion and is expected to grow at a CAGR of 13.9% by 2026. The growing trend was reflected by Green Wednesday sales
• MCOA has expanded its interests into Latin America and has strategic partnerships in place, as well as wholly-owned subsidiaries in its portfolio
• Leadership team has set high standards for the company and plans to leverage the strategic partnerships it has accumulated as a means of facilitating growth for the company within the industry

The cannabis industry just celebrated its second-largest holiday of the year – Green Wednesday, the industry’s very own “Black Friday.” According to software company Akerna’s figures, the sale of legal cannabis products during the four-day holiday (November 24-27) is likely to have topped $251 million. The forecast also estimated that sales would equate to a 78% spike from normal daily sales on Green Wednesday, resulting in $90 million worth of legal products being sold (https://ibn.fm/gcGjw). The Green Wednesday sales increase reflects a growing trend of the industry as a whole. The global cannabis market was valued at $22.10 billion in 2020 and is expected to grow at a CAGR of 13.9% during the 2021 to 2026 forecast period. Much like other industries around the world, the marijuana market was significantly impacted by the COVID-19 pandemic. The limitations placed on brick-and-mortar establishments presented many setbacks and forced store owners to seek other methods to sell products, like on social media platforms and e-commerce sites (https://ibn.fm/oWxDU). In the interest of global expansion, Marijuana Company of America (OTC: MCOA) has taken steps to extend the company’s reach into new regions, including Latin America, and to leverage current strategic partnerships with several companies and its wholly-owned subsidiaries to facilitate growth in an industry that continues to expand despite recent setbacks. Companies that MCOA has partnered with include:

• Cannabis Global Inc. (OTC: CBGL) – CBGL is an up-and-comer in the cannabis industry. It has a growing product and intellectual property portfolio. The company is currently marketing and producing an innovative cannabis storage, transport, and tracking solution called Comply Bag(TM) and is the developer and marketer of the Hemp You Can Feel(TM) brand.
• Eco Innovation Group Inc. (OTC: ECOX) – MCOA’s investment supports ECOX’s cutting-edge and innovative extraction technology. The technology utilizes a proprietary formulation that extracts bioactive compounds from cannabidiol (“CBD”) which is combined with plant-based materials creating a fluid and cost-effective outcome.
• Natural Plant Extract – NPE is a direct investment interest that operates a licensed cannabis manufacturing and distribution business in Lynwood, California. NPE’s Type 7 California manufacturing and distribution license allows for product distribution anywhere in the State of California.

MCOA’s wholly-owned subsidiaries include:

• hempsmart(TM) – A CBD company focused on creating and promoting the most effective and best tasting products with the highest quality on the market. During 2021, the company rebranded and took a fresh take on its packaging – leveraging a social media campaign to entice customers to purchase its premier products, including Smart Drops, Neuro Smart, and Smart Cream.
• cDistro – cDistro is the company’s distribution arm for CBD brands, along with smoke and vape shop-related products, wholesalers, c-stores, specialty retailers, and consumers across North America. cDistro has been selected as one of the first to distribute Marley One.
• VBF Brands Inc. – MCOA’s acquisition of VBF will offer exponential growth potential with other nearby properties, which the company will have the opportunity to work with as a result of the acquisition.

MCOA’s leadership team sets high standards of integrity and professionalism for the company’s employees, officers, and directors. As the company expands into new regions around the world, it intends to utilize its resources and strategic partners’ success to continue diversifying is product and services and provide consistent value to its shareholders while securing a leading position on the legal cannabis and industrial hemp markets. For more information, visit the company’s website at www.MarijuanaCompanyofAmerica.com. NOTE TO INVESTORS: The latest news and updates relating to MCOA are available in the company’s newsroom at http://ibn.fm/MCOA

• Several factors could contribute to 12.71% projected CAGR in nootropics global market
• Rise in demand for cognitive enhancers (smart drugs that enhance memory and focus) is expected to foster growth
• The Happy Co. has become the category creator for Happy Coffee and a recognized leader in natural nootropics

A recent Verified Market Research report noted that the global market for nootropics reached $2.42 billion in 2020 and is projected to top $6.29 million by 2028, growing at a CAGR of 12.71% from 2021 to 2028 (https://ibn.fm/MdSBu). Sharing Services Global (OTCQB: SHRG) subsidiary The Happy Co., a direct-sales opportunity that offers functional beverages, capsules, patches and creams featuring nootropics, could see significant benefit from this growth. “The rise in demand for cognitive enhancers or smart drugs among the global population in order to enhance memory and stay focused is expected to foster the growth of the global nootropics market,” the report stated. “The rising focus of manufacturers to develop natural or organic ingredients-based supplements in order to target customers is likely to drive the market growth.” The report went on to note that increase in demand from the sports industry for mind-boosting drugs will also impact the market. “The popularity and acceptance of nootropics as an enhancement or medication is attracting new market players in this market, which will lead to the growth of the nootropics market,” the report continued. “Increasing awareness regarding the importance of psychological wellness and accessibility of these medications at various online and offline platforms are among the key components impelling the development of the nootropics market.” In addition, nootropics drugs, which work as antidepressants, energy boosters, and anxiety resistance, could see increased R&D efforts, the report observed. “Due to their large benefits, they are preferred by individuals, and hence this is expected to encourage R&D in the nootropics market. Newer technological innovations in the nootropics market will lead to the growth of this industry.” One of the fastest-growing companies in the social-marketing and direct-selling industries, SHRG subsidiary The Happy Co. has become the category creator for Happy Coffee and a recognized leader in natural nootropics. The company offers a wide array of nootropic products, from oils and capsules to patches and powders. Each offering has been carefully formulated to provide the knowledge that comes from experience, which the Happy Co. is confident will prove the value and worth of its products to eager consumers everywhere. Sharing Services Global Corporation is a publicly traded diversified company dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer. Its primary division includes Elevacity U.S. LLC, the parent company of the Happy Co. and a sales and marketing company based on utilization of independent contractors as the sales force. For more information, visit the company’s websites at www.SHRGInc.com and www.TheHappyCo.com. NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG